Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)

IT-DIAB (Therapeutic Innovation in Type 2 Diabetes) : Prospective Follow-up of a Cohort of Patients With Pre-diabetes Over 10 Years

The main objective of the study is to follow prospectively a cohort of patients with pre-diabetes to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population.

Inclusion Criteria:

• Adult patients (≥18 years)
• Subjects with diabetes risk score ≥ 15
• Subjects with impaired fasting glucose: blood glucose ≥ 1.10 g/l and < 1 .26 g/L
• Subjects affiliated with an appropriate social security system

Exclusion Criteria:

• Fasting glycemia ≥ 1.26 g/l
• Fasting glycemia ≤ 1.10 g/l
• Subjects previously treated with oral anti-diabetic: metformin, glitazones, inhibitors of α-glucosidase, sulfonylurea, repaglinide, inhibitors of DPP-IV, GLP-1 R agonists.
• Subjects previously treated with insulin, except gestational diabetes
• Severe coagulation disorders
• Thrombocytopenia < 100 000/mm 3
• Severe psychiatric disorders
• Severe renal insufficiency (creatinine clearance < 30 ml/min)
• Severe hepatic insufficiency (TP < 50%)
• Alcohol abuse (> 30g/j)
• Patient's opposition
• Subject unable to follow the study during the 5 years of follow-up
• Subject exclusion period in a previous study